New drug shows promise for Tough-to-Treat advanced bladder cancer

NCT ID NCT03474107

Completed Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested whether a new drug called enfortumab vedotin helped people with advanced bladder cancer live longer than standard chemotherapy. It involved 608 adults whose cancer had spread or returned after previous treatments with immunotherapy and platinum-based chemotherapy. Researchers directly compared survival, tumor response, side effects, and quality of life between the new drug and chemotherapy groups.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Benaroya Research Institute at Virginia Mason

Seattle, Washington, 98101, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Florida Hospital

Orlando, Florida, 32804, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
HOPE Cancer Center of East Texas

Tyler, Texas, 75701, United States
Innovative Clinical Research

Whittier, California, 90606, United States
Lifespan Rhode Island Hospital

Providence, Rhode Island, 02903, United States
Long Island Jewish Medical Center

Lake Success, New York, 11042, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Montefiore Medical Center

The Bronx, New York, 10467, United States
Nebraska Cancer Specialists

Omaha, Nebraska, 68130, United States
Norton Cancer Institute

Louisville, Kentucky, 40207, United States
Providence Portland Med Center

Portland, Oregon, 97213, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
Rush University Medical Center

Chicago, Illinois, 60612, United States
Saint Francis Hospital

Greenville, South Carolina, 29607, United States
Sidney Kimmel Center for Prostate and Urologic Cancers

New York, New York, 10065, United States
Site AR54001

Buenos Aires, Argentina
Site AT43001

Salzburg, Austria
Site AT43004

Vienna, Austria
Site AT43005

Linz, Austria
Site AU61001

Miranda, Australia
Site AU61002

Sydney, Australia
Site AU61004

St Leonards, Australia
Site AU61006

Adelaide, Australia
Site BE32001

Ghent, Belgium
Site BE32003

Leuven, Belgium
Site BE32005

Hasselt, Belgium
Site BE32007

Brussels, Belgium
Site BE32008

Ghent, Belgium
Site BE32009

Liège, Belgium
Site BE32010

Charleroi, Belgium
Site BE32011

Aalst, Belgium
Site BE32013

Brussels, Belgium
Site CA15001

Sherbrooke, Canada
Site CA15002

Montreal, Canada
Site CA15004

Québec, Canada
Site CA15005

Toronto, Canada
Site CA15007

Montreal, Canada
Site CA15008

Saskatoon, Canada
Site CA15011

Oshawa, Canada
Site CA15012

Edmonton, Canada
Site CA15013

Vancouver, Canada
Site CA15014

London, Canada
Site CA15015

Calgary, Canada
Site CH41001

Chur, Switzerland
Site CH41002

Bern, Switzerland
Site DE49003

Tübingen, Germany
Site DE49008

Heidelberg, Germany
Site DE49009

Würzburg, Germany
Site DE49010

Münster, Germany
Site DE49011

Essen, Germany
Site DK45001

Herlev, Denmark
Site DK45003

Aalborg, Denmark
Site DK45004

Copenhagen, Denmark
Site ES34001

Barcelona, Spain
Site ES34002

Badalona, Spain
Site ES34003

Madrid, Spain
Site ES34005

Seville, Spain
Site ES34007

Valencia, Spain
Site ES34008

Valencia, Spain
Site ES34010

Badajoz, Spain
Site ES34011

Manresa, Spain
Site ES34012

Barcelona, Spain
Site ES34013

Madrid, Spain
Site ES34014

Córdoba, Spain
Site ES34015

Madrid, Spain
Site ES34017

Madrid, Spain
Site ES34019

Pamplona, Spain
Site ES34023

Barcelona, Spain
Site FR33001

Brest, France
Site FR33002

Strasbourg, France
Site FR33003

Nice, France
Site FR33004

Saint-Mandé, France
Site FR33005

Pierre-Bénite, France
Site FR33006

Villejuif, France
Site FR33009

Bordeaux, France
Site FR33014

Marseille, France
Site FR33015

Lyon, France
Site FR33016

Caen, France
Site FR33018

Bordeaux, France
Site FR33019

Toulouse, France
Site FR33021

Besançon, France
Site FR33022

Paris, France
Site GB44002

Sheffield, United Kingdom
Site GB44004

Metropolitan Borough of Wirral, United Kingdom
Site GB44005

London, United Kingdom
Site GB44006

London, United Kingdom
Site GB44011

Southampton, United Kingdom
Site GB44013

Sutton, United Kingdom
Site IT39004

Terni, Italy
Site IT39008

Arezzo, Italy
Site IT39010

Milan, Italy
Site IT39013

Pisa, Italy
Site IT39014

Reggio Emilia, Italy
Site IT39019

Cremona, Italy
Site IT39025

Modena, Italy
Site JP81001

Kyoto, Japan
Site JP81002

Yokohama, Kanagawa, Japan
Site JP81003

Okayama, Japan
Site JP81004

Hiroshima, Japan
Site JP81005

Sendai, Miyagi, Japan
Site JP81006

Toyama, Japan
Site JP81007

Sapporo, Hokkaido, Japan
Site JP81008

Bunkyo-ku, Tokyo, Japan
Site JP81009

Kita-gun, Kagawa-ken, Japan
Site JP81010

Hirosaki, Aomori, Japan
Site JP81011

Ube, Yamaguchi, Japan
Site JP81012

Koto-ku, Tokyo, Japan
Site JP81013

Shinjuku-ku, Tokyo, Japan
Site JP81014

Kashiwa, Chiba, Japan
Site JP81015

Chiba, Japan
Site JP81016

Sayama, Osaka, Japan
Site JP81017

Niigata, Japan
Site JP81018

Morioka, Iwate, Japan
Site JP81019

Fukuoka, Japan
Site JP81020

Tsukuba, Ibaraki, Japan
Site JP81021

Tokushima, Japan
Site JP81022

Osaka, Japan
Site JP81023

Fukuoka, Japan
Site JP81024

Takatsuki, Osaka, Japan
Site JP81026

Sapporo, Hokkaido, Japan
Site KR82001

Seongnam-si, South Korea
Site KR82002

Incheon, South Korea
Site KR82003

Seoul, South Korea
Site KR82004

Seoul, South Korea
Site KR82005

Shin, South Korea
Site KR82006

Daejeon, South Korea
Site KR82007

Goyang-si, South Korea
Site KR82008

Seoul, South Korea
Site KR82009

Seoul, South Korea
Site KR82010

Seoul, South Korea
Site KR82012

Hwasun-gun, South Korea
Site NL31001

Tilburg, Netherlands
Site NL31002

Amsterdam, Netherlands
Site NL31003

Amsterdam, Netherlands
Site NL31009

Nijmegen, Netherlands
Site PT35102

Lisbon, Portugal
Site PT35105

Lisbon, Portugal
Site PT35106

Porto, Portugal
Site RU70002

Ivanovo, Russia
Site RU70005

Omsk, Russia
Site RU70009

Obninsk, Russia
Site RU70015

Vologda, Russia
Site TW88601

Tainan, Taiwan
Site TW88602

Kaohsiung City, Taiwan
Site TW88604

Taipei, Taiwan
Site TW88605

Kaohsiung City, Taiwan
Site TW88606

Taichung, Taiwan
Site TW88607

Taoyuan District, Taiwan
Smilow Cancer Hospital at Yale-New Haven

New Haven, Connecticut, 06510, United States
Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States
Toledo Clinic Cancer Center

Toledo, Ohio, 43623, United States
UCI Chao Family Comprehensive Cancer Center

Orange, California, 92868, United States
University of California

Sacramento, California, 95817, United States
University of Colorado

Denver, Colorado, 80045, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
White Plains Hospital Center for Cancer Care - Oncology Site

White Plains, New York, 10601, United States

Conditions

Explore the condition pages connected to this study.

BLADDER CANCER URETERAL CANCER UROTHELIAL CANCER